Discovery of a new series of [1,2,4]triazolo[4,3-a]quinoxalines as dual phosphodiesterase 2/phosphodiesterase 10 (PDE2/PDE10) inhibitors

被引：22

作者：

Andres, Jose-Ignacio ^{[1
]}

Buijnsters, Peter ^{[2
]}

De Angelis, Meri ^{[1
]}

Langlois, Xavier ^{[3
]}

Rombouts, Frederik ^{[2
]}

Trabanco, Andres A. ^{[1
]}

Vanhoof, Greet ^{[4
]}

机构：

[1] Janssen Cilag SA, Janssen Res & Dev, Toledo 45007, Spain

[2] Janssen Pharmaceut NV, Janssen Res & Dev, Neurosci Med Chem, B-2340 Beerse, Belgium

[3] Janssen Pharmaceut NV, Janssen Res & Dev, Neurosci Biol, B-2340 Beerse, Belgium

[4] Janssen Pharmaceut NV, Janssen Res & Dev, CREATe, Translat Sci, B-2340 Beerse, Belgium

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2013年 / 23卷 / 03期

关键词：

Neurological disorders; PDE2; inhibitors; PDE10; Triazoloquinoxalines; CGMP; PDE10A; CAMP; RAT; STRIATUM; MEMORY; BRAIN;

D O I：

10.1016/j.bmcl.2012.11.077

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

The synthesis, preliminary evaluation and structure-activity relationship (SAR) of a series of 1-aryl-4-methyl[1,2,4]triazolo[4,3-a]quinoxalines as dual phosphodiesterase 2/phosphodiesterase 10 (PDE2/PDE10) inhibitors are described. From this investigation compound 31 was identified, showing good combined potency, acceptable brain uptake and high selectivity for both PDE2 and PDE10 enzymes. Compound 31 was subjected to a microdosing experiment in rats, showing preferential distribution in brain areas where both PDE2 and PDE10 are highly expressed. These promising results may drive the further development of highly potent combined PDE2/PDE10 inhibitors, or even of selective inhibitors of PDE2 and/or PDE10. (c) 2012 Elsevier Ltd. All rights reserved.

引用

页码：785 / 790

页数：6

共 22 条

[11] Cyclic nucleotide phosphodiesterases and their role in endocrine cell signaling
Mehats, C
Andersen, CB
Filopanti, M
Jin, SLC
Conti, M
[J]. TRENDS IN ENDOCRINOLOGY AND METABOLISM, 2002, 13 (01) : 29 - 35
[12] Phosphodiesterases in the CNS: targets for drug development
Menniti, Frank S.
Faraci, W. Stephen
Schmidt, Christopher J.
[J]. NATURE REVIEWS DRUG DISCOVERY, 2006, 5 (08) : 660 - 670
[13] cGMP, but not cAMP, in rat hippocampus is involved in early stages of object memory consolidation
Prickaerts, J
de Vente, J
Honig, W
Steinbusch, HWM
Blokland, M
[J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 2002, 436 (1-2) : 83 - 87
[14] The atypical anxiolytic drug, tofisopam, selectively blocks phosphodiesterase isoenzymes and is active in the mouse model of negative symptoms of psychosis
Rundfeldt, Chris
Socala, Katarzyna
Wlaz, Piotr
[J]. JOURNAL OF NEURAL TRANSMISSION, 2010, 117 (11) : 1319 - 1325
[15] Inhibition of the striatum-enriched phosphodiesterase PDEIOA: A novel approach to the treatment of psychosis
Siuciak, Judith A.
Chapin, Douglas S.
Harms, John F.
Lebel, Lorraine A.
McCarthy, Sheryl A.
Chambers, Leslie
Shrikhande, Alka
Wong, Stephen
Menniti, Frank S.
Schmidt, Christopher J.
[J]. NEUROPHARMACOLOGY, 2006, 51 (02) : 386 - 396
[16] Isolation and characterization of a dual-substrate phosphodiesterase gene family: PDE10A
Soderling, SH
Bayuga, SJ
Beavo, JA
[J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (12) : 7071 - 7076
[17] Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functions
Soderling, SH
Beavo, JA
[J]. CURRENT OPINION IN CELL BIOLOGY, 2000, 12 (02) : 174 - 179
[18] Stange H., 2010, Patent Applications, Patent No. [WO 2010054260 A1 20100514, 2010054260]
[19] Stange H., 2010, [No title captured], Patent No. [WO 2010054253 A1 20100514, 2010054253]
[20] mRNA expression patterns of the cGMP-hydrolyzing phosphodiesterases types 2, 5, and 9 during development of the rat brain
van Staveren, WCG
Steinbusch, HWM
Markerink-Van Ittersum, M
Repaske, DR
Goy, MF
Kotera, J
Omori, K
Beavo, JA
De Vente, J
[J]. JOURNAL OF COMPARATIVE NEUROLOGY, 2003, 467 (04) : 566 - 580

← 1 2 3 →